The tumor microenvironment.Ubiquitin-Specific Peptidase 36 Proteins Storage & Stability Journal for ImmunoTherapy of Cancer 2018, 6(Suppl 1):Page 265 ofReferences 1. Demark-Wahnefried W, Platz EA, Ligibel JA, Blair, CK Courneya KS, Meyerhardt JA, et al. The Function of Obesity in Cancer Survival and Recurrence. Cancer Epidemiology, Biomarkers, and Prevention. 2012 Aug;21(eight):1244-59. Ethics Approval The study was approved by the Emory University Institutional Critique Board, approval number IRB00100973.Fig. three (abstract P506). See text for descriptionFig. 1 (abstract P506). See text for descriptionTable 1 (abstract P506). MVA of fat threat with survivalP507 Body mass index as a predictor of survival in advanced stage cancer sufferers treated with immunotherapy Julie Shabto, BA1, Dylan Martini, BA1, Yuan Liu, PhD2, Milton Williams1, Amir Khan1, Colleen Lewis3, Hannah Collins3, Mehmet Akce2, Haydn Kissick2, Bradley Carthon, MD, PhD2, Walid Shaib, MD2, Olatunji Alese, MD2, Conor Steuer, MD2, Christina Wu, MD2, David Lawson, MD2, Ragini Kudchadkar, MD2, Bassel El-rayes, MD2, Suresh Ramalingam, MD2, Viraj Master, MD, PhD2, Taofeek Owonikoko, MD, PhD2, R. Donald Harvey, PharmD2, Mehmet Bilen, MD2 1 Emory University School of Medicine, Atlanta, GA, USA; 2Emory University, Atlanta, GA, USA; 3Winship Cancer Institute, Atlanta, GA, USA Correspondence: Mehmet Bilen ([email protected]) Journal for ImmunoTherapy of Cancer 2018, 6(Suppl 1):P507 Background Physique mass index (BMI) has been investigated as a prognostic issue for cancer patients , Endothelin Receptor Type A (EDNRA) Proteins Biological Activity however the effect of BMI on clinical outcomes in patients on phase 1 clinical trials employing immunotherapy-based remedy will not be recognized. We investigated the association between BMI and survival in advanced staged cancer patients treated with immunotherapy. Techniques We completed a retrospective evaluation of 90 patients treated on phase 1 clinical trials making use of immunotherapy-based therapy regimens at Winship Cancer Institute of Emory University from 2009-2017. Baseline BMI was collected in the electronic health-related records. Overall survival (OS) and progression-free survival (PFS) had been measured from the initially dose of immunotherapy to date of death or hospice referral and radiographic or clinical progression, respectively. Cox proportional hazard model was applied for association with OS and PFS. BMI was analyzed as a continuous variable and as a categorical variable (normal or underweight: BMI 25, overweight: 25 BMI 30, obese: BMI 30). Outcomes Most individuals (59) were males along with the majority (81) have been Royal Marsden Hospital (RMH) excellent risk. About two-thirds (69) of sufferers received at the very least two lines of systemic therapy before being treated with immunotherapy around the clinical trial. Melanoma (33), gastrointestinal (22), and lung and head neck (20) had been one of the most prevalent tumor sorts. The median BMI was 27.four. When treated as a continuous variable in multi- variable analysis, a greater BMI was substantially associated with longer OS and PFS (Table 1). Individuals having a typical or underweight BMI had drastically shorter OS (HR: three.27, p-value: 0.005) and trended towards shorter PFS when in comparison with overweight and obese patients. The median OS and PFS of obese individuals was 19.1 months and 4.7 months, respectively, though median OS and PFS of typical or underweight sufferers was 6.7 months and 1.9 months and median OS and PFS for overweightFig. two (abstract P506). See text for descriptionJournal for ImmunoTherapy of Cancer 2018, six(Suppl 1):Web page 266 ofpatients was eight.six months and two.3 months,.